Novel Tia Biomarkers Identified by Mass Spectrometry-Based Proteomics

George, Paul‐Louis; Mlynash, Michael; Adams, Christopher M.; Kuo, Calvin J.; Albers, Gregory W.; Olivot, Jean‐Marc

doi:10.1111/ijs.12603

Cited by 27 publications

(16 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding might be explained by the fact that TIA triggers a cascade of molecular mechanisms and neurometabolic events that not necessarily result in evident structural changes and parenchymal damage to the brain and therefore may not be detectable using glial or neuronal proteins in serum. Other markers of microvascular damage, thrombosis and neurotoxicity may more appropriately capture pathophysiological mechanisms underlying TIA and are currently under extensive investigation as surrogate markers for TIA diagnosis 35 36 .…”

Section: Discussionmentioning

confidence: 99%

Assessment of Serum UCH-L1 and GFAP in Acute Stroke Patients

Ren

Kobeissy

Alawieh

et al. 2016

Sci Rep

View full text Add to dashboard Cite

A rapid and reliable diagnostic test to distinguish ischemic from hemorrhagic stroke in patients presenting with stroke-like symptoms is essential to optimize management and triage for thrombolytic therapy. The present study measured serum concentrations of ubiquitin C-terminal hydrolase (UCH-L1) and glial fibrillary astrocytic protein (GFAP) in acute stroke patients and healthy controls and investigated their relation to stroke severity and patient characteristics. We also assessed the diagnostic performance of these markers for the differentiation of intracerebral hemorrhage (ICH) from ischemic stroke (IS). Both UCH-L1 and GFAP concentrations were significantly greater in ICH patients than in controls (p < 0.0001). However, exclusively GFAP differed in ICH compared with IS (p < 0.0001). GFAP yielded an AUC of 0.86 for differentiating between ICH and IS within 4.5hrs of symptom onset with a sensitivity of 61% and a specificity of 96% using a cut-off of 0.34ng/ml. Higher GFAP levels were associated with stroke severity and history of prior stroke. Our results demonstrate that blood UCH-L1 and GFAP are increased early after stroke and distinct biomarker-specific release profiles are associated with stroke characteristics and type. We also confirmed the potential of GFAP as a tool for early rule-in of ICH, while UCH-L1 was not clinically useful.

show abstract

Section: Discussionmentioning

confidence: 99%

Assessment of Serum UCH-L1 and GFAP in Acute Stroke Patients

Ren

Kobeissy

Alawieh

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…A recent study with a small sample size used mass spectroscopy-based proteomics to identify serum biomarkers of minor stroke and TIA. By verification in a second cohort of patients, platelet basic protein was identified as a candidate serum biomarker for TIA [20].…”

Section: Platelet Basic Proteinmentioning

confidence: 98%

Blood Biomarkers in Minor Stroke and Transient Ischemic Attack

Wang

2016

Neurosci. Bull.

View full text Add to dashboard Cite

Minor stroke and transient ischemic attack (TIA) are common disorders with a high rate of subsequent disabling stroke, so the early recognition and management of minor stroke and TIA is of great importance. At the moment, the diagnosis of these disorders is based on neurologic deficits in a stroke-clinician's examination of the patient, supplemented by the results of acute brain imaging. However, high variability in TIA diagnosis has been reported between physicians, even trained vascular neurologists, and image-based diagnostic confirmation is not always readily available. Some patients still have ischemic events despite sustained standard secondary preventive therapy. Blood biomarkers are promising to aid in the diagnosis, risk stratification, and individual treatment of minor stroke and TIA. Some studies are being conducted in this field. This mini-review aims to highlight potential biomarkers for diagnosis and those helpful in predicting the risk of future stroke and the selection of treatment.

show abstract

“…From the 8 candidates, GDIR1, DRP2, and CNTN1 were altered in patient serum samples, which may well serve as biomarkers for long-term stroke prognosis. Utilizing MS-based proteomics, ceruloplasmin, complement component C8 gamma, and platelet basic protein have been shown to be significantly different between the ischemic patients (n = 35) and the controls (n = 12) [11]. And, platelet basic protein was further identified as a candidate serum biomarker for a transient ischemic attack.…”

Section: Studies Performed In Human Brain Tissue/cerebrospinal Fluid/mentioning

confidence: 99%

Proteomic-Based Approaches for the Study of Ischemic Stroke

You

et al. 2019

Transl. Stroke Res.

View full text Add to dashboard Cite

Novel Tia Biomarkers Identified by Mass Spectrometry-Based Proteomics

Cited by 27 publications

References 29 publications

Assessment of Serum UCH-L1 and GFAP in Acute Stroke Patients

Assessment of Serum UCH-L1 and GFAP in Acute Stroke Patients

Blood Biomarkers in Minor Stroke and Transient Ischemic Attack

Proteomic-Based Approaches for the Study of Ischemic Stroke

Contact Info

Product

Resources

About